Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1993-03-01
1995-07-04
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
562623, 514576, 514408, A61K 3119, A61K 3140
Patent
active
054300584
DESCRIPTION:
BRIEF SUMMARY
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to biomimetic iron carriers useful for iron removal from mammalian cells and from pathogenic organisms infecting mammals, including humans.
Iron is an essential metal for the growth of all organisms as it participates in several vital processes such as oxygen metabolism and electron transfer reactions, nucleic acid synthesis and a variety of enzyme catalysis. Microorganisms, primarily the bacteria and fungi, obtain iron from their environment by secretion of low molecular weight siderophores that bind iron (III) at high affinity (K.sub.a >10.sup.30) and return to the cell surface where iron delivery occurs via receptor mediated uptake.
Iron (III) chelators are important as therapeutic tools for the treatment of iron overload and of infectious diseases caused by iron-dependent pathogens, such as malaria caused by Plasmodium falciparum (Dionis, J. B. et al., 1991 CRC Handbook of Microbial Iron Chelates (ed. by G. Winkelmann), pp. 309-338. Early efforts to improve the performance of iron chelation agents in medicine have been directed at synthesis of analogs of enterobactin family which display high affinity for iron (III) and mobilize iron from ferric proteins (Kontoghiorghes, G. J. and Evans, R. W., 1985, FEBS Lett., 189:141-144; Kontoghiorghes, G. J., 1986 Biochem. J. 233:299-302; Kretchmar, S. A. and Raymond, K. N., 1986, Am. Chem. Soc. 108:6212-6218; Tufano, T. P. et al., 1981, Biochim. et Biophys. Acta 668:420-428). These agents have limitations for use in vivo due to their restricted membrane permeation properties (Shanzer, A. and Libman, J., 1991 CRC Handbook of Microbial Iron Chelates (ed. by G. Winkelmann) pp. 309-338) and their propensity to remove iron (III) from both ferritins and transferrin (Tufano, T. P. et al., 1981, Biochim. et Biophys. Acta 668:420-428; Hider, R. C. 1984, Struct. and Bond 5:25-84). On the other hand, the use of the natural siderophore, desferrioxamine B (DFO), in iron chelation therapy has scored a wide success, mainly due to the capacity of the hydroxamates to chelate iron from ferritin and the relatively slow scavenging of iron from transferrin. However, DFO has to be administered by infusion and causes several side effects (Porter, J. 1989, Eur. J. Haematol. 43:271-285).
Previous attempts to employ synthetic iron binders as in vitro and in vivo growth inhibitors of intraerythrocytic parasites scored some success (Scheibel, L. W. and Adler, A. (1981) Mol. Pharmacol. 20: 218-223, and 22: 140-144; Scheibel, L. W. and Stanton, G. G. (1986) Mol. Pharmacol. 30: 364-369; Scheibel, L. W. and Rodriguez, S. (1989) in Malaria and the red cell, Alan R. Liss Inc. 2: 119-149; Heppner, D. G., et al., (1988) Blood 72: 358-361; Raventos-Suarez, C., et al. (1982) Am. J. Trop. Med. Hyg. 31: (5), 919-922; Stahel, E., et al. (1988) Am. J. Trop. Med. Hyg. 39: 236-240; Pollack, S. (1983) British J. Haematol, 53: 181-183). However, each class of compounds thus far examined has shown some drawbacks. Synthetic dithiocarbamates and hydroxyquinolines proved efficacious, because of their high permeation features, but the fact that their antimalarial potency depends on their forming cytotoxic metal complexes has seriously curtailed their use (Scheibel, L. W. and Rodriguez, S. (1989) in Malaria and the red cell, Alan R. Liss Inc. 2: 119-149). Synthetic, lipophilic catecholates which acted as specific iron scavengers and showed satisfactory membrane penetration, appeared also of limited use because they demonstrably deplete serum iron pools (Heppner, D. G., et al., (1988) Blood 72: 358-361).
The present invention relates to iron (III) carriers which are designed to overcome the above limitations and to show: (1) high selectivity for iron; (2) permeation across cellular membranes including infected erythrocytes; (3) metabolic resistance by being built from enantiomers of natural amino acids; (4) lack of growth promotion activity towards pathogenic organisms by not binding to siderophore receptors present in said organisms, and (5) l
REFERENCES:
patent: 3247197 (1966-04-01), Gaeumann et al.
patent: 4966997 (1990-10-01), Shanzer et al.
patent: 5149845 (1992-09-01), Shanzer et al.
Shanzer et al.: "Reversed siderophores act as antimalarial agents", Proc. tl. Acad. Sci. USA, vol. 88, No. 15, Aug. 1991, pp. 6585-6589.
Shanzer et al.: "Receptor mapping with artificial siderophores", Pure & Appl. Chem., vol. 61, No. 9, 1989, pp. 1529-1534.
Shanzer et al.: "Synthetic ferrichrome analogues with growth promotion activity for Arthrobactor flavescens", Biochemical and Biophysical Research Communications, vol. 157, No. 1, Nov. 30 1988, pp. 389-394.
Y. Tor et al.: "Biomimetric ferric ion carriers. Chiral ferrichrome analogoues", Journal of the American Chemical Society, vol. 109, No. 21, Oct. 14, 1987, pp. 6518-6519.
Stilfen et al.: "Bioflavonoid Effects on In Vitro Cultures Of Plasmodium falciparum", Biological Pharmacology, vol. 37, No. 22, 1988, pp. 4269-4276.
Tufano et al.: "Kinetics of Iron Release From Ferritin To Catechoylamide", Biochimica et Biophysica Acta, vol. 668, 1981, pp. 420-428.
Hersko et al.: "Deferoxamine Inhibition Of Malaria Is Independent Of Host Iron Status", J. Exp. Med., vol. 168, Jul. 1988, pp. 375-387.
Raventos-Suarez et al.: "Plasmodium Falciparum: Inhibition Of In Vitro Growth By Desferrioxamine", The American society of Tropical Medicine and Hygiene, vol. 31(5), 1982, pp. 919-922.
Goldberg et al.: "Hemoglobin degradation in the malaria parasite PLASMODIUM FALCIPARUM: An ordered process in a unique organelle", National Acadaemy Of Science, vol. 87, Apr. 1990, pp. 2931-2935.
Lytton et al.: "Reversed Siderophores as Antimalarial Agents", The American Society for Pharmacology and Experimental Therapeutics, vol. 40 pp. 584-590. (1988).
Dionis et al.: "Therapeutically Useful Iron Chelators", Handbook of Microbial Iron Chelates, 1991, pp. 339-357.
G. J. Kontoghiorghes, "Iron mobilization from ferritin using .alpha.-oxohydroxy heteroaromatic chelators", J. Biochem., 1986, vol. 233, pp. 299-302.
G. J. Kontoghioreghes, et al. "Site specificity of iron removal from transferrin by .alpha.-ketohydroxypyridine chelators", FEBS Letters, vol. 189, No. 1, pp. 141-144. (1989).
L. W. Scheibel et al. "Antimalarial Activity of Selected Aromatic Chelators", Molecular Pharmacology, vol. 22:140-144. (1990).
L. W. Scheibel et al. "Antimalarial Activity of Selected Aromatic Chelators II. Substituted Quinolines and Quinoline-N-oxides", Molecular Pharmacology, 20:218-223. (1989).
L. W. Scheibel et al., "Antimalrial Activity of Selected Aromatic Chelators. IV. Cation Uptake by Plasmodium falciparum in the Presence of Oxines and Siderochromes," Molecular Pharmacology vol. 30. 364-369. (1988).
S. Kretchmar et al., "Biphasic Kinetics and Temperature Dependence of Iron Removal from Transferrin by 3,4-LICAMS", J. Am. Chem. Soc., 1986, 108, 6212-6218.
D. G. Heppner, et al., "Antimalarial Properties of Orally Active Iron Chelators", Blood, vol. 72, No. 1 (1988) pp. 358-361.
A. Shanzer, "Biomimetic Siderophores", CRC Handbook of Microbial Iron Chelates, pp. 309-338. (1982).
R. Hider, "Siderophore Mediated Absorption of Iron", pp. 27-85. (1983).
S. Pollack, "Annotation Malaria and Iron", British Journal of Haematology, 1983, 53, 181-183.
E. Stahel, et al. "Iron Chelators: in vitro inhibitory effect on the liver stage of rodent and human human malaria", Am. J. Trop. Hyg. 39(3), 1988 pp. 236-240.
E. J. Haematol et al. "Oral iron chelators: prospects for futrue development", J. Haematol 1989:43, pp. 271-285.
Cabantchik Ioav Z.
Libman Jacqueline
Shanzer Abraham
Criares T. J.
Henley III Raymond
Yeda Research and Development Co. Ltd.
Yissum Research and Development Co. of the Hebrew University of
LandOfFree
Pharmaceutical compositions comprising hydroxamate derivatives f does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising hydroxamate derivatives f, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising hydroxamate derivatives f will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-760446